RxDoctor Payments DataLook up a doctor →

Nikesh Seth, MD

Pain Medicine · Scottsdale, AZNPI 1922327030

Payments from drug & device makers

$53,044in general payments, 2019–2025

Across 759 payments — averaging $69.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lexicon Pharmaceuticals, Inc.$38K
  • Abbott$5K
  • Vertiflex, Inc.$2K
  • Boston Scientific$1K
  • AbbVie$1K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$1K
  • plus $4K from 50 others

What the payments were for

  • Travel & lodging$1,76612%
  • Food & beverage$13,34588%
  • Education$540%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$53,044 in reported general payments places this provider in the 90th percentile of 180 pain medicine providers in Arizona.

See all pain medicine providers in Arizona

Medicare billing

Part B allowed, 2024
$1,132,429
Medicare patients
890
Services billed
23,105

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BelbucaBuprenorphine Hcl12$8,820
Oxycodone Hcl151$2,147
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl15$1,723
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen49$1,485
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen85$1,453
Gabapentin61$728
Cyclobenzaprine Hcl42$662
Morphine Sulfate18$600
Pregabalin20$559
Buprenorphine Hcl30$419
Hydromorphone Hcl13$287
Morphine Sulfate ErMorphine Sulfate15$264
Acetaminophen-CodeineAcetaminophen With Codeine14$246
Tizanidine Hcl18$218
Tramadol Hcl30$209

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Belbuca$666$8,82012 claims
Hikma Pharmaceuticals USABuprenorphine-Naloxone, Morphine Sulfate, Buprenorphine Hcl$78$2,74263 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 180 pain medicine providers in Arizona.

Other pain medicine in Scottsdale

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →